Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Finlee 10 mg dispersible tablets.
| Pharmaceutical Form |
|---|
|
Dispersible tablet. White to slightly yellow, round, biconvex 6 mm tablet debossed with “D” on one side and “NVR” on the other. |
Each dispersible tablet contains dabrafenib mesilate equivalent to 10 mg of dabrafenib.
Excipient with known effect: Each dispersible tablet contains <0.00078 mg of benzyl alcohol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dabrafenib |
Dabrafenib is an inhibitor of RAF kinases. Oncogenic mutations in BRAF lead to constitutive activation of the RAS/RAF/MEK/ERK pathway. BRAF mutations have been identified at a high frequency in specific cancers, including approximately 50% of melanoma. Dabrafenib demonstrated suppression of a downstream pharmacodynamic biomarker (phosphorylated ERK) and inhibited cell growth of BRAF V600 mutant melanoma cell lines, in vitro and in animal models. |
| List of Excipients |
|---|
|
Mannitol (E421) |
Opaque white high-density polyethylene (HDPE) bottle with polypropylene child-resistant screw cap and a silica gel desiccant.
Each bottle contains 210 dispersible tablets and two 2 g desiccant canisters. Patients should be instructed to keep the desiccant canisters in the bottle and not to swallow them.
Packs containing:
Each dosing cup is 30 ml in volume with 5 ml graduated increments.
Not all pack sizes may be marketed.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
EU/1/23/1767/001-002
15 November 2023
| Drug | Countries | |
|---|---|---|
| FINLEE | Estonia, France, Croatia, Ireland, Italy, Lithuania, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
